Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186975 | 0.87 | MTNR1A (0.36) | TAAR1MAOB | |
| SCHEMBL25844870 | 0.82 | MAOB (0.34) | ALDH1A1CYP3A4LTC4SSMN1; SMN2MAOB | |
| SCHEMBL25845153 | 0.81 | ALOX5 (0.36) | ALDH1A1CYP3A4LTC4SMAOBPOLB | |
| SCHEMBL5271445 | 0.80 | ALDH1A1 (0.35) | ALDH1A1CYP3A4LTC4SSMN1; SMN2MAOB | |
| SCHEMBL11081166 | 0.79 | AHR (0.47) | ALDH1A1CYP3A4SMN1; SMN2MAOBAHR | |
| SCHEMBL6542530 | 0.77 | CYP3A4 (0.39) | ALDH1A1CYP3A4NQO2SMN1; SMN2MAOB | |
| SCHEMBL12484333 | 0.76 | NPC1 (0.37) | ALDH1A1CYP3A4NQO2SMN1; SMN2POLB | |
| SCHEMBL14337789 | 0.75 | DHFR (0.49) | ALDH1A1CYP3A4SMN1; SMN2MAOBPOLB | |
| SCHEMBL9921215 | 0.74 | CYP3A4 (0.37) | ALDH1A1CYP3A4MAOB | |
| SCHEMBL10044946 | 0.74 | ALDH1A1 (0.47) | ALDH1A1CYP3A4SMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216283-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2017-08-03 | — | — | US | disclosed |
| US-20170216283-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2017-08-03 | — | — | US | disclosed |
| US-9657001-B2 | Compounds and uses | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657001-B2 | Compounds and uses | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216283-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | ALDH1A1 268/4885CYP3A4 215/4885NQO2 279/4885 |
| US-20160326143-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | ALDH1A1 268/4885CYP3A4 215/4885NQO2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.